Laboratorio de Hematobiología, Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Mexico City 07738, Mexico.
CONACyT Fellow-ICAT, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Biosensors (Basel). 2022 Sep 29;12(10):806. doi: 10.3390/bios12100806.
Arterial hypertension (HTN) is a global public health concern and an important risk factor for cardiovascular diseases and renal failure. We previously reported overexpression of ENaC on the plasma membrane of human platelets is a hallmark of HTN. In this double-blinded study of an open population ( = 167), we evaluated the sensitivity and specificity of a diagnostic assay based on gold nanoparticles (AuNPs) conjugated to an antibody against epithelial sodium channel (ENaC) expressed on platelets, which is detected using a fluorescent anti-ENaC secondary antibody and spectrofluorometry. Using the cutoff value for the AuNP-anti-ENaC assay, we confirmed the diagnosis for 62.1% of patients with clinical HTN and detected 59.7% of patients had previously undiagnosed HTN. Although some shortcomings in terms of accurately discriminating healthy individuals and patients with HTN still need to be resolved, we propose this AuNP-anti-ENaC assay could be used for initial screening and early diagnosis to critically improve opportune clinical management of HTN.
动脉高血压（HTN）是一个全球性的公共卫生关注点，也是心血管疾病和肾衰竭的一个重要风险因素。我们之前曾报道，人血小板质膜上 ENaC 的过度表达是 HTN 的一个显著特征。在这项针对开放性人群（n=167）的双盲研究中，我们评估了一种基于金纳米颗粒（AuNPs）与针对血小板上表达的上皮钠离子通道（ENaC）的抗体相偶联的诊断检测方法的灵敏度和特异性，该方法使用荧光抗 ENaC 二级抗体和分光荧光光度法进行检测。使用 AuNP-抗 ENaC 检测方法的截止值，我们确认了 62.1%的有临床 HTN 患者的诊断，并检测到 59.7%的之前未被诊断出的 HTN 患者。尽管在准确区分健康个体和 HTN 患者方面仍存在一些不足之处需要解决，但我们提出，这种 AuNP-抗 ENaC 检测方法可用于初始筛查和早期诊断，以显著改善 HTN 的临床管理时机。
